Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD112R is a co-inhibitory immune checkpoint receptor preferentially expressed on immune cells, especially NK cells, NKT cells, and T cells. Its primary ligand is CD112 (Nectin-2). CD112R inhibits T cell receptor–mediated signaling, leading to reduced cytokine production and proliferation in T cells. Targeting the CD112R–CD112 axis can enhance anti-tumor immunity, making it a potential target for cancer immunotherapy.
Checkpoint blockade; disruption of CD112R-CD112 interaction enhances anti-tumor immunity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD112 receptor (CD112R).